Drug profile · INN
palovarotene
SOHONOS
palovarotene (SOHONOS) is a retinoic acid receptor gamma agonist. Associated with Ipsen. Route of administration: oral. Current US regulatory status: approved.
Drug details — palovarotene
- US status
- approved
- Class
- Musculo-skeletal system (M09)
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
palovarotene (SOHONOS) is a retinoic acid receptor gamma agonist. Associated with Ipsen. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Retinoic acid receptor gamma agonist
Primary target: Retinoic acid receptor gamma
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | refused | — |
| TGA | approved | — |
Related & competitor drugs
Frequently asked questions
What is palovarotene?
palovarotene (SOHONOS) is a retinoic acid receptor gamma agonist. Associated with Ipsen. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for palovarotene?
SOHONOS is a marketed brand name for palovarotene. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of palovarotene?
palovarotene has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.